Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Talpaz

Showing results (51-60 of 263) with videos related to

Pageof 27
Sort By:
Cancer Research|November 4, 2010
Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosisVaibhav Kapuria, Luke F Peterson, Dexing Fang, et al.
American Journal of Hematology|March 24, 2017
Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosisMalathi Kandarpa, Yi-Mi Wu, Dan Robinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repairEunice Laurent, David L Mitchell, Zeev Estrov, et al.
Cancer|March 29, 2002
Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemiaSrdan Verstovsek, Hagop Kantarjian, Taghi Manshouri, et al.
Blood|January 2, 2003
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571Nicholas J Donato, Ji Yuan Wu, Jonathan Stapley, et al.
Hematology/Oncology Clinics of North America|July 24, 2004
Investigational strategies in chronic myelogenous leukemiaJorge E Cortes, Susan M O'Brien, Francis Giles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemiaMoshe Talpaz, Ashok Rakhit, Karen Rittweger, et al.
Oncotarget|July 2, 2014
Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathwayHarish Potu, Luke F Peterson, Anupama Pal, et al.
Plos One|July 30, 2010
PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawalShreya Kanodia, Eric Wieder, Sijie Lu, et al.
Cancer|June 16, 2004
Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemiaAlfonso Quintas-Cardama, Hagop Kantarjian, Susan O'Brien, et al.
Pageof 27

Showing results (51-60 of 263) with videos related to

Sort By:
Pageof 27
Cancer Research|November 4, 2010
Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosisVaibhav Kapuria, Luke F Peterson, Dexing Fang, et al.
American Journal of Hematology|March 24, 2017
Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosisMalathi Kandarpa, Yi-Mi Wu, Dan Robinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repairEunice Laurent, David L Mitchell, Zeev Estrov, et al.
Cancer|March 29, 2002
Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemiaSrdan Verstovsek, Hagop Kantarjian, Taghi Manshouri, et al.
Blood|January 2, 2003
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571Nicholas J Donato, Ji Yuan Wu, Jonathan Stapley, et al.
Hematology/Oncology Clinics of North America|July 24, 2004
Investigational strategies in chronic myelogenous leukemiaJorge E Cortes, Susan M O'Brien, Francis Giles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemiaMoshe Talpaz, Ashok Rakhit, Karen Rittweger, et al.
Oncotarget|July 2, 2014
Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathwayHarish Potu, Luke F Peterson, Anupama Pal, et al.
Plos One|July 30, 2010
PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawalShreya Kanodia, Eric Wieder, Sijie Lu, et al.
Cancer|June 16, 2004
Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemiaAlfonso Quintas-Cardama, Hagop Kantarjian, Susan O'Brien, et al.
Pageof 27